AVIR

Atea Pharmaceuticals, Inc.

Healthcare
Biotechnology
$425M market cap

Forecast run · Sep 14, 2026Upside rank 959 of 3,136

Model Signal

ForecastQ Daily Probabilities

45.8%

39.5%

27.2%

Analyst Consensus

Recommendation3.00/5 Hold

Last price$5.31

Price target$7.00

Implied move+31.8%

Analysts4

ForecastQ Portfolios

AVIR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.